Yahoo Web Search

Search results

1. • 

     Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet

     Zacks via Yahoo Finance· 3 hours ago

     The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock....

2. • 

     Euro 2024: Your complete guide

     The Telegraph via Yahoo Sports· 30 minutes ago

     As well as using recycled polyester and water-based ink, the ball is made from more sustainable bio-based materials than any previous Adidas official...

3. • 

     3 Penny Stocks to Buy Now: May 2024

     InvestorPlace· 4 days ago

     Penny stocks to buy carry a considerable amount of risk. Because it may also be difficult to find quotations for penny stocks, they may be impossible to...

4. • 

     Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

     Zacks via Yahoo Finance· 5 days ago

     HI-Bio in-licensed exclusive rights to develop and commercialize felzartamab across all indications...

5. • 

     Lilly (LLY) Hits Record High on Crohn's Disease Study Data

     Zacks via Yahoo Finance· 6 days ago

     You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest...

6. • 

     Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

     Zacks via Yahoo Finance· 2 hours ago

     Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and...

7. • 

     Compagnie Léa Nature buys French peer Biothentic’s bulk organic foods unit

     Just Food via Yahoo Finance· 4 days ago

     We transmit commercial activity, but also complete production and sector know-how." For Léa Nature,...

8. • 

     Here's Why Investing in Donaldson (DCI) Stock Makes Sense Now

     Zacks via Yahoo Finance· 5 days ago

     Donaldson (DCI) benefits from strength in the Industrial Solutions segment and accretive...

9. • 

     Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B

     BioPharma Dive via Yahoo Finance· 6 days ago

     The deal, only Biogen’s third since the start of 2018, is a sign the company is open to branching...

10. • Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human...

      Morningstar· 6 days ago

      HI-Bio’s lead asset, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to selectively deplete CD38+ cells including plasma ...